A Study to Evaluate How Safe and Effective is the Mixture of Lipiodol® Ultra Fluid and Glue When Used for Embolization Procedures

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 132 participants.

Also called NCT02625389

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 132 participants (enrolled count) (from the registry)
Sponsor
  • Guerbet Registry lists this organization as the lead sponsor
Registry
  • NCT NCT02625389
  • CTRI CTRI/2017/05/008607
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
India (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02625389. Allocation not applicable; no masking; primary purpose treatment. Start 2017-11-29 (actual); primary completion 2021-05-12 (actual). Results posted on 2025-10-10.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study to Evaluate How Safe and Effective is the Mixture of Lipiodol® Ultra Fluid and Glue When Used for Embolization Procedures
Condition
Congenital Hemangioma
Condition
Hemangioendothelioma
Condition
Angiosarcoma
Condition
Arteriovenous Malformations
Intervention (Drug)
Lipiodol Ultra Fluid with surgical glues
Lead sponsor
Guerbet (class: industry)

Record details

Record id
cardio:ct-nct02625389
Content hash
9b248e8cf852c1ad6287a03f83459c02cae22b3dc0becf9272d06bebffbce105